Production (Stage)
Esperion Therapeutics, Inc.
ESPR
$1.17
-$0.03-2.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -40.46M | -21.32M | -29.52M | -61.93M | 61.02M |
| Total Depreciation and Amortization | 26.00K | 27.00K | 26.00K | 10.00K | -- |
| Total Amortization of Deferred Charges | 699.00K | 172.00K | 447.00K | 442.00K | 437.00K |
| Total Other Non-Cash Items | 5.07M | 7.48M | 6.15M | 59.27M | 14.17M |
| Change in Net Operating Assets | 12.03M | -21.31M | -12.42M | -5.00M | -21.80M |
| Cash from Operations | -22.63M | -34.95M | -35.33M | -7.21M | 53.83M |
| Capital Expenditure | -- | 0.00 | -167.00K | -77.00K | -73.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 0.00 | -167.00K | -77.00K | -73.00K |
| Total Debt Issued | -- | 99.73M | -- | -- | -- |
| Total Debt Repaid | -- | -210.09M | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 531.00K | 9.07M | 96.44M |
| Repurchase of Common Stock | -- | -47.00K | 0.00 | -343.75M | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -7.50M | 145.41M | -9.63M | 304.66M | -5.83M |
| Cash from Financing | -7.50M | 35.00M | -9.10M | -30.02M | 90.61M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -30.13M | 44.00K | -44.59M | -37.31M | 144.36M |